MedTrace Logo

A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

NCT05194839 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2023-06-29

Study results available
· View outcomes & findings →

Summary

A 12-week Randomized, Double-blind, Placebo-controlled, Dose Ranging Phase 2 Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis followed by an Open-label Extension Phase.

Conditions

  • Palmoplantar Pustulosis

Interventions

DRUG

RIST4721

RIST4721 tablets, 100 mg are blue, oval, biconvex film-coated tablets

DRUG

Placebo

Matching placebo

Sponsors & Collaborators

  • Aristea Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-05
Primary Completion
2023-02-13
Completion
2023-03-06
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Czechia
  • Germany
  • Hungary
  • Poland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05194839 on ClinicalTrials.gov